In the current study, we found that dual inhibition of PRMT1 and SMARCA4 resulted in profound synergistic anti-neoplastic activity against SMARCA4-R1157W mutant CRC cells in vivo and in vitro. This evidence concerns the gene SMARCA4 and colorectal carcinoma.